Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy

By P. P. Toth. 2012

2,522 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/47d71520c317fb93207eea15630aabe7a329d0aa

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

I. Graham
T. Ivanova
D. Lloyd‐Jones
V. Basevi
Sidney C. Smith
F. Cosentino
J. Perk
W. Kernan

Citations in the corpus

Reprint: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. (2014, background): “Indeed, AIM-HIGH (9) demonstrated the futility of adding niacin in indiv i uals with low HDL–C and high triglycerides, and ACCORD (14) demonstrated the futility of adding fenofibrate in persons with diabetes.”
2016 European Guidelines on cardiovascular disease prevention in clinical practice (2017, unknown): “Furthermore, there is no evidence of clinical benefit for this combination [386].”
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. (2015, methodology): “8% women) with established ASCVD were randomized to extended-release niacin 1500 to 2000 mg per day or matching placebo.(388) All patients received simvastatin, 40 to 80 mg per day plus ezetimibe 10 mg per day, if needed, to maintain an LDL-C level of 40 to 80 mg/dL.”
Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. (2014, background): “in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) trial.(81)”
Standards of Medical Care in Diabetes—2012 (2011, background): “The trial was halted early due to no difference in the primary CVD outcome and a possible increase in ischemic stroke in those on combination therapy (270).”
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY. (2016, unknown): “on Global Health Outcomes [AIM-HIGH] and Heart Protection Study 2—Treatment of HDL to Reduce the Incidence of Vascular Events [HPS2-THRIVE]) failed to show CVD protection during the 3- and 4-year trial periods, respectively (212,213); by design, betweengroup differences in LDL-C were nominal at 5 mg”
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. (2016, methodology): “Niacin did not reduce strokeover long-termfollow-up inpatientswithCVDintheAIM-HIGH and HPS2-THRIVE trials.(251,252) In fact, the increased rate of ischaemic stroke in the AIM-HIGH trial and the trend (P 1⁄4 0.”
Hyperlipidemia as a Risk Factor for Cardiovascular Disease (2012, result): “In a meta-analysis of 38,153 statin treated subjects in whom nonHDL-C, LDL-C and Apo-B were compared, all three markers were predictive of CVD, with non-HDL-C showing a slightly greater association than the other two (18).”
2016 European Guidelines on cardiovascular disease prevention in clinical practice. (2016, background): “Furthermore, there is no evidence of clinical benefit for this combination.(386) Fibrates, particularly fenofibrate, may be useful, not only for decreasing high triglyceride concentrations and increasing low HDL-C, but for lowering LDL-C further when used with a statin.”
Standards of Medical Care in Diabetes—2014 (2013, background): “It can significantly increase blood glucose at high doses, but at modest doses (750–2,000 mg/day), significant improvements in LDL cholesterol, HDL cholesterol, and triglyceride levels are accompanied by only modest changes in glucose that are generally amenable to adjustment of diabetes therapy (37”
Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. (2013, background): “In the Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health Outcomes (AIM-HIGH) trial, 3414 patients with established vascular disease on a statin with low HDL and high triglycerides were randomized to extended release niacin or placebo.(131) N”